More information: www.ndpharmabiotech.com

13 15

STRATEGY UPDATE

ND Pharma & Biotech´s short term strategy 2013-2015

2

Welcome to our 13-15 Strategy Update. At ND P&B our main goal is to improve the quality of human life by enabling people to live better and longer, preventing all kinds of health problems that may has cause or arise from the excessive introduction and incorporation of Chem-Tox ingredients to the food chain and related industry. This is why we created and adopted a mission under a single logo, called: MAKING LIFE BETTER.

Notice limitations on Director liability under English Law Under the UK Companies Act 2006, a safe harbor limits the liability of Directors respect of statements in and omissions from the report of the directors contained within The Company annual report and other published materials, which include and/or may include a business review. Under English Law the directors would be liable to the company, but not to any third party, if the Report or reported information within contain errors as a result of recklessness or knowing misstatement or dishonest concealment of a material fact, but would not otherwise be liable. This report and information contained within has been drawn up and presented in accordance with and in reliance upon English company law and the liabilities of the Directors in connection with that report shall be subject to the limitations and restrictions provided by such law.

Cautionary statement regarding forward-looking statements This strategy review and the written information released, or oral statements made, to the public in the future by or on behalf of the company and/or group, may contain forward-looking statements. Forward-Looking statements give the company current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate”, “estimate”, “expect”, “intend”, “will”, “project”, “plan”, “believe”, and other words and terms of similar meaning in connection with any discussion for future operating or financial performance. In particular, these include statements relating to the future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results, The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-Looking statements involve inherent risks and uncertainties. The company cautions investors that a number of important factors, including some exposed within the present document, could cause actual results to differ materially from those contained in any forward-looking statement. Such factors include but are not limited to those related as “risk factors” contained between other in our annual report C(4) Document.

3

ND P&B 13-15 As a global company, our commercial success depends o us creating innovative products and brands, valued and making these accessible to as many people and sectors who need them as possible. The period 2013-2015 will be marked by a challenging global economic climate. Despite this, we have continued to make good progress in our strategy to grow business in a sustainable way, delivering our products worldwide and running for new and promising associations with first class partners administering first class brands that are valuing our efforts and progresses in R+D and simplifying their operations. All this issues made possible to us to create a strong value chain to all our products.

OUR GROWING Since initial operations, we have grown from zero to actual positioning, thanks to a careful programmed launch and a careful programmed initiation of operations within the sector. Our financial results are marked by debt incurred from prior stages of R+D+i and the efforts made in programming and excise the company from its matrix group, to advance and turn walk independently. The financial situation is in excess favorable to our shareholders, with consolidated results that presume a new age of satisfaction and accomplishments without precedent to a family-owned private company like this, sustaining growing on its own success and operation results.

Highlights

+210m£

Total value of company´s shares 0£

Debt with creditors and operators worldwide

300% Average growing in net sales/year sustained +750m£

Calculated value of Research Portfolio and IP rights 500% Average growing by sectors and regions

expected

4

From the desk of our CEO

We are facing without any doubt to the worse financial and consumer´s crisis from the last two centuries. Our company has started operations in the middle of this reversing and challenging environment and specifically within a sector that is resulting unfairly damaged by the financial and political nightmares the developed world are facing up today. This situation and our own philosophy, made possible to us to deploy all our imagination and capacities to improve our performance and growth prospects, to reduce risks to the minimum expression and to enhance our results as company that re-invest the vast majority of our earnings in R+D+I and the consolidation of our IP ownership of rights. The benefits of such strategy are being evident during the time we are operating within the sectors taken, with strong performances in our emerging markets and the re-positioning of some of our products and technologies at the forefront of industrial processes as far as legislative and regulatory rules are changing looking to the way we think and create our value, especially in the field of toxic-chemical restrictions within their use in the foodstuffs and industrial food processing. Unfortunately, we are seeing some of our most promising projects within the healthcare industry and medical and human care field, delayed due to regulatory affairs, and the deep crisis the pharmaceutical sectors are facing worldwide, specifically where other competitors are gathering as much as they can the public and financial resources governments are employing to sustain a constantly debilitating situation to the healthcare systems in developed countries. So we expect more success within this fields in a near future. Our food division is performing quite well as we were able to adapt research resources to the high demanding-low research in comparison food and nutrition industry. We are helping clients to develop new and more successful formulas for nutritional necessities and demands, as well as solutions to long expected improvements within the quality and safe of actual presentations and processes of some alimentary materials and processed aliments, making they more natural, safe and tasteful. We developed and are evolving important associations with first class companies worldwide to license our IP rights, products, and technologies to drive expansive process to our brands and co-brands, under safe and less risky win-win formulas. We are expanding quickly our net of agents and distributors to guaranteed presence and delivery worldwide. In other hand, we are looking for new developments and markets, and in summary, we are looking permanently for new and substantial ways to improve our performance within this environment, acting with responsibility and ethically, stronger and resilience, to overcome this dark period of economy and moral loosening, that created the worse-imaginable scenario for industries and consumers. This is why we are also increasing our worldwide presence even in under-developed areas, thorough solidary projects, developments and cooperation. Jess P. Harford

5

CEO´s review We have diversified our sources of growth, our R+D productivity has significantly improved and our processes are simpler and more efficient. Our strategy is delivering.

When we started to implement and defining our strategy for success in business, we set out a model of performance to increase growth, reduce risks and improve our financial situation in the mid and long term due to the constrictions existing, specially when you´re coming of a long period of R+D without commercial activity or produce, and when your capitalization is relatively low in comparison with the expenditures made or incurred to achieve a number of intellectual property ownership and the exclusive developments protected by our industrial secrets. The truth is that we made an outstanding progress since we open widely operation thanks to the cutting edge positioning and the sharp skills and intelligence of our management team from one to one responsibilities to the collective performance, that can be marked as said, outstanding. During the next years we expect an increase in operations exceeding the 500% to the total sales made till 2012, sectoring such growth within different spaces from emerging markets and development countries to Asia-Pacific, Middle-East and Africa, to other well established as Europe, The Americas and Russia. We are pushing for an investment within those markets, and establishing a platform to growth on the R+D productivity, simplifying or just changing our business to make it more flexible and adaptable to the actual factual situation over the world changes, taking care of the complexities of global trading and using different tool and technologies to keep it simple transforming our weak points into strong so onto those areas where we can rely and improve our processes including the manufacturing, commerce and distribution. We strengthen our core business to continue the excellent progress our people is having within the principal areas of development, increasing focus on our own portfolio, improving our offer on healthcare and developing a wider strategy to access to API´s and Biochemical molecules, having account that we have syntheses and unique processes developed that are on the major satisfaction of our main clients worldwide, including some of the most exigent manufacturers within the cosmetic, pharmaceutical and nutrition areas. We operate with responsibility and making further advances on our agenda to ensure our behavior an actions meeting or exceeding the expectations of society on a company with a mission like ours. Transparency, ethics and CSR, will preside our all our actions, involving our central values as people not only as a company.

6

What we do

We are a science-led global healthcare and biotech company that reseraches and develops a broad range of innovative products. We are leading providers in fine chemicals, biochemicals, organics, API´s, nutrition, ingredients and a broad range of own developed product´s portfolio.

We have three primary areas of business; Pharma-Business, Food & Nutrition and Agri-Business. Other areas include our TRADING department for fine chemicals and some commodities, (250 references) API´s, (12.500 references) and building block molecules where we have a reference catalog of 150.000 different references. We provide top quality and safe chemicals, with a broad selection of products and a strong quality assurance performance methodology to verify and test that every product delivered is comply with most exigent and rigorous requirements, exceeding in most cases the quality specifications and conformational standards set out by our competitors. We provide ingredients and molecules to some of the TopTen Pharmaceutical companies worldwide, and the principal Cosmetic Industry manufactures within Europe and The United States of America. We maintain an own product´s portfolio and own brands, that are reaching unexpected quote of success worldwide, remarking some of our food and nutrition star brand PreserFoodTM/® achieving advances as being the first substitute to sulphytes within meat products or the revolutionizing milk market PreserFood TM/Dairy®, that is repositioning the standards within the industry of milk and milk-derived products worldwide. Our product´s pipeline is always increasing its value, as we are progressing towards new and unexpected progresses within different areas of health and disease from Trigeminal Neuralgia to VIH, and our ever growing NeuroScience Research Lab that is also progressing towards a treatment and/or cure of several threatening diseases as refractory schizophrenia and memory disorders, as well as others like Treatment-Resistant Depressive Disorders (TRDD) We are developing a novel vaccine to Herpes Simplex and a novel approach to 3rd Generation Inhaled Ergotamines for the treatment of Adult Persistent Migraine, and other interesting approaches to healthcare problems, unmet or unresolved till now. Our commercial business and branches are structured around regional units and/or focusing areas. We have an outsourcing team that is developing every business region and attending worldwide necessities and demands in an evolved business model developed specifically to attend such demand with a maximum efficiency and capacity on a contention cost and risk reduction policy that we´re sure will be our key for future success. The management team is leaded in every regional area by one of our team leaders, surrounded by a sounded and experiential group of knowledgeable and concerned people.

7

How we create value Delivering sustainable innovation

and expanding access to our products we create value for society and our clients, their business and the company

We see both opportunities and challenges in our operating environment. Scientific research is continuously uncovering new understandings about diseases processes and life technologies. Meanwhile, the world´s population continues to grow, as do pressures on healthcare costs, with a notable intensification in developed markets following the recent macro-economic downturn.

Our assets Intellectual Property, people and infrastructure

Our strategic priorities Grow, Deliver, Simplify

Our values Transparency, Respect, Integrity,

Ethical Behavior and People focused

Del iver sustainable innovation

and products

and expand access to

them

Company Value Creation

Benefits to society, clients, customers and business

Re-Investment

8

Where we do it Our geographic presence covers a wide spectrum of countries and territories

9

Where we make it Our production plants cover

all areas of our current business

10

Our Families of Products chemicals & biochemicals Amino Acids Analytical Reagents Antibacterials Antibiotics APIs Biochemicals Boronic Acids Brominated Products Buffers Carbohydrates Chiral Compounds Chlorinated Products Coumarins Coupling Reagents Crown Ethers Detergents

Diagnostic Raw Materials Fluorinated Products Furans HPLC Reagents Hydrazines Hydroquinones Imidazoles Indazoles Indoles Inorganic Chemicals Iodinated Products Linkers Naphthalenes Oxazoles Peptide Reagents Phenols Picolines Piperazines Pyrans

Pyrazines Pyrazoles Pyridines Pyrimidines Pyrroles Quaternary Ammonium salts Quinines Quinolines Research Organics & Inorganics Stains & Indicators Sugars Tetralones Tetrazoles Thiadiazoles Thiazoles Thiophenes Triazines Triazoles Water Analysis

11

The ND Pharma & Biotech PEOPLE

President of The Board

Chief Executive Officer

Chief Scientific Officer

Director Managing Director Chief Financial Officer

Chief Comptroller

Chief Lab & Research

Chief Circulation Officer

Chief Regulation Officer

Head Logistics

Sales Manager

Head of Development and operations

Head Production Officer

Head Legal Counsel

Chief Procurement Officer

Regional and National Representatives, Agents, Distributors, Commercial and Sales Mangers, Operating Officers, Plant Managers, Researchers, Scientists, Administrative and Allied People, etc.

12 The BOARD ND Pharma & Biotech´s BOARD is composed by key and relevant figures within the Company and some other counsels that has chair and assist to the meetings offering expertise, experience, relevant area knowledge or counsel.

Composition is made by:

1. The President of The Board of Directors. (1) 2. The Vice- President and Chairman of The Board of Directors. (1)

3. The General Secretary. (1) 4. The Head Legal Counsel. (1)

5. Economic Advisor/President of Audit Committee. (1) 6. Directors from all relevant areas. (4)

7. Representatives from shareholders and family. (1) 8. Independent Members of The Board. (3)

13

ND Pharma & BiotechNEW MARKETS

OPENING

Current Markets and Products are being complemented with ready to order products from our Production Plants both in Netherlands and Belgium operated by our Strategic Partner B&A. PRODUCT RANGES Oils, Butters and Extracts From almond oil to Sage oil or Wheat germ oil. Sweeteners ACEK-250 & Stevia Alternative Preservatives Further Raw Materials Dextrin Hyaluronic Acid L-Hyistidin L-Methionin USP Squalene Natural Vitamin E Taurin JP15

14

ND Pharma & BiotechNEW MARKETS

FOOD & NUTRITION

Current Markets and Products are being complemented with ready to order products from our Production Plants both in Netherlands and Belgium operated by our Strategic Partner B&A. PRODUCT RANGES Amino-Acids & Derivatives From A to Z (Alanine to Valine) all range of amino-acids and derivatives Preservatives From Benzoic Acid to Propylparaben and mixes of single preservatives. Oils, Butters and Extracts (Fine Chemicals) Aloe Vera (Gel, Concentrate, Oil, Powder, Normal & Organic). Bee Propolis (different qualities). Coenzyme Q10 Cranberry Oil Galee royal Green coffee oil Jojoba Oil DSP. ADSP. Malic Acid, MKP,MSP, AMSP, KKP,SAPP, SPP, TKPP,TSP, Vitamin C, Vitamin E Acetate, etc.

15

ND Pharma & BiotechNEW MARKETS

COSMETIC INDUSTRY

Current Markets and Products are being complemented with ready to order products from our Production Plants both in Netherlands and Belgium operated by our Strategic Partner B&A. PRODUCT RANGES STARCHES FOR COSMETICS From AGENASORB DRY RICEGEL to ORGANIC MALTODEXTRINE or Rice NS/DSA7/PFA11 PRESERVATIVES FOR COSMETIC INDUSTRY From PARA ANISIC ACID to PHENOCHEM or TRICLOSAN SILICONES Alkyl-Modified silicones, Cyclosiloxanes, Methylsilicones, Taylor-made Grades SWEETENERS NATRIUMSACCHARIN 450X TO XYLITOL FURTHER RAW MATERIALS From Allantoin EP to Xantan Gum (Food and Pharma grades) SOLVENTS Butylene Glycol 1-3 Glycerine 88,5% to 99,5% EP Qualities Monopropylene Glycol USP/EP Tripropylene Glycol

16

How we Deliver ND Pharma & Biotech

Grow A diversif ied global business We have created a balanced business and product portfolio, capable of delivering sustainable sales growth. This is centered on our main core business areas, Pharma Business (including Cosmetics, food & Nutrition and Agri-Business, which provide us with significant competitive advantages and opportunities for synergy. We have increased our investment in higher growth areas such as emerging markets and Pacific Asia Region, with a boom ahead for our operations within Latin American Countries including Brazil. We are developing and exploring forward looking associations with major national, European and Multinational companies to open new markets and products creating important synergies to an open wide new category of products and brands from broad wide distribution to luxury cosmetics and sales organizations interested in partnership, joint venture and or licensing of our products and technologies, IP protected.

17

ND Pharma & Biotech Style

Del iver More products of value We have changed our R+D organization and partnerships so that it is now better able to offer and sustain a complete pipeline of research and innovation products, even with a range of flexible options to offer sustainable innovation opportunities of growing and improvement to our existing clients, their problems and certain situations that rise up constantly as industry evolves. We have increased externalization of our research, allowing us to access to new areas od science and to share the risks associated to the development with some of our partners. We changed also our decision-making processes so actually we confer continuity and further development only to those realistic projects which may mean a significant different with existing therapies and solutions. We have broken the traditional endogamy and hierarchical business model (in relation to R+D) creating smaller, better oriented, drive and motivated scientists working groups that are accountable for their own projects. All this supervised by a dynamic scientific department leaded by experts in their fields, with a minimum experience of 25 years in the sector.

18

ND Pharma & Biotech MADE it SIMPLE

Simpli fy The way we operate As our business is an evolving and ever-changing model adopting different shapes, we are in a process of transformation how we operate so that we can reduce the complexities associated to this industry sectors to become more efficient. A global restructuration we implemented is designed to deliver significant savings and cost contention to be able to support investment in our priority growth business area as well as offset pressures on the company margin results from changes in de developing business model. Such savings must to be generated across the business, to let us to verify efficiency and continue to development and design of more advanced ways of efficacy and competency within our logistics and the associations with retailers and other industry operators in difficult areas and territories where most variables and obstacles for growing came form legislations, regulators and competitors monopolistic behavior settled within such territories.

19

ND Pharma & Biotech FINANCIAL ARCHITECTURE

Financial Architecture Our financial architecture is designed to support the delivery and execution of the Company´s strategy, and drive sustainable growth in core earnings per share and free cash flow in order to maximize total returns to invest, re-invest and satisfy our shareholders. This architecture is based on four key financial priorities; sustainable sales growth, improving our operating leverage, improving our financial efficiency and converting more of our earnings into cash. By applying this framework we can drive better and more consistent decision-making processes across the company and improve delivery of our key financial objectives of earnings per share growth and free cash flow generation. This can be returned to company and society by different ways as investing in acquisitions and licenses, re-invested in more efficient and advanced R+D and planning future directions for the company towards the uncertainties existing in the markets, countries and world in general. We are improving also our data gathering and reporting systems to let the financial people to exercise more control over the progress and alignment of our results and our designed architecture, making us more efficient within simplicity.

20

ND Pharma & Biotech

BRANDS &PRODUCTSPERFORMANCE

18BRANDS

PRESERFOODTM Antiox Carnosol Cured Dairy Flavor Marine Meat Mix Nature Nature Pack Olive Shellfish Sweet Sweet Forte Uovo Wine Wine Plus Wine Forte

23FoodBrands Acarisin Acek 250 Acqualife React Acqualife Juice Alkiow Anisakill Chiknsafe Cocqwa Inofish Fruitfresh Lactolife M.A.R.S. Mohostop Mohostop Panificación Moldstop Moldstop C Moldstop C Adapted formula Puremeat Puremeat 100 Mearsafe Sterilfood Vegafresh Zoeltar

6BRANDS

AGRIBUSINESS ACARISIN TM ACARISIN TM GARDEN OXALISILK OXALIPLUS I OXALIPLUS II FRUITFRESH TM

11pharmaBrands ACNIFOL BACTERSKIN BACTERSKIN 5000 DBX TM GLICOSPART NOOGLUTIL NOOPEPTIL ND 507 LIFESAVER PSORIACRIM TANCREAM ZELITEM

21

ND Pharma & Biotech CONSUMERbrands

4BRANDSWATER ALKALINE IONIZED WATER #1Worldwide

GLAICE

• Regular (Food) • Silver (premium PET) • Gold (Glass) • Diamond (LED lighted Glass Bottle)

GLAICE SPORT GLAICE DEEP SEA Water GLAICE XEOS ( Ice Spheres) KANGEN WATER by GLAICE KANGEN WATER (unbranded)

1BRANDWATERPRODUCTION SYSTEM

ALKIOW Dropper/Bott le ALKIOW Single-Dose Bl ister ALKIOW Industr ial

GLAICE 0´0%

CARBON FOOTPRINT PRODUCT

22

ND Pharma & Biotech SPECIAL PRODUCTS 12.561REFERENCED

COMPOUNDS

ON CATALOG

ON DEMAND BY ALPHABETICAL ORDER FROM AMINOPICOLINIC ACID (00001) TO HEXAMETHYLDISILAZANE (12561) Including Special Molecules

Subject to availability and quotation/Certain restrictions apply under certain circumstances

+

23

ND Pharma & Biotech BUILDING BLOCK MOLECULES +150.000NCE´s

Novel Chemical Entities

Chiral, heterocyclic small, cyclic fused ring compounds

with one or more chemical handles as well as a variety of alicyclic, Spiro and aromatic, etc. to assist medicinal and synthetic chemists in developing hit generation and hit-to-

lead optimization libraries. Compounds available in multi-gram (1-100) purity (+95%)

Making them suitable for high-throughput and combinatorial syntheses or scale-up of lead compounds.

Ex-Stock (commonly used) and prompt dispatch (72 Hrs).

Available On-Line and .pdf database. (abridged). +API´s +BORONIC ACIDS +SCREENING COMPOUNDS +NOVEL PRODUCTS

24

ND Pharma & Biotech IDENTIFIY & MANAGE RISKS

BOARD OF DIRECTORS The Board of Directors is responsible for our system of corporate governance,

strategy, risk management and financial performance

AUDIT & RISK COMMITTEE The Board has delegated responsibility for reviewing and approving to the Audit

and Risk Committee to oversee the adequacy and effectiveness of controls.

CORPORATE EXECUTIVE TEAM The CET supports the CEO in the management of ND Pharma & Biotech Company

business activities accountable to Risk Oversight and Compliance Council

BUSINESS UNITS Leadership Teams are responsible for their own operations and accountable to the

CEO and the supporting committees

RISK MANAGEMENT AND COMPLIANCE BOARD The RMCB oversee management of all business units and all risks that are

considered important for their respective BU´s, including those risks that are designated as significant to ND Pharma & Biotech as a whole.

25

ND Pharma & Biotech RESPONSIBLEBUSINESS

During next period we will increase the emphasis over the Responsible Business policy we have generated from the very

beginning within our company. This special strategy is relying upon a core values and ideals that are quite clear for all those

involved in operations with us, with a central idea subscribed within our minds; access and transparency in both ways direction.

Our commercial success is directly linked to operating in a trustworthy and responsible way and environment. We report our approach and the progress we are making across four fundamental areas:

• Health for everyone • Correct Behavior • Trust in Our People • Our Planet

These innovative approach to the vision of the company embraces also other values as using innovative science to create value, improving access to our products and to healthcare advances with a targeting in neglected cases, tropical and subtropical populations and disfavored classes and populations groups. We encourage our people also to support health and well being in our communities and to operate within sales and marketing with ethical conduct and trusted attitude acting in strict accordance with CSR in every moment. We promote also the work with healthcare professionals, food technicians and experts of industry sectors where we operate to facilitate that access to our products and sales operations and implementation. With a diverse workforce coming from all sectors and backgrounds we aspire to build-up a diverse community also within our small world that company is, at all. We strongly recommend to all our people a fair-play attitude towards any operator involved, even competitors and other runners within this complex business sector and industrial field.

26

ND Pharma & Biotech MAKING LIFE BETTER

27 © 2013 ND Pharma & Biotech ALL RIGHTS RESERVED.

Reproduction forbidden. No parts of this document should be reproduced, copied and/or transmitted unless written permission from the owner of rights. These include any electronic, physic or mechanic means including oral transmission. ND Pharma & Biotech reserves any right to correct, amend and/or alter the content of this document even without prior notice. When authorized to reproduction, that should be of the document in its integrity and in no way separate sheets and or extracted content. The data and statements contained within the present document does not constitute an offer, invitation to treat and/or negotiation proposal to any third party, neither should be taken as economic and/or investment advise. The company denies any responsibility or liability for losses incurred or investments made as a consequence of the lecture of present document. To any query related to the information presented, please write directly to: Mary S Kay Chief Financial Officer ND Pharma & Biotech cfo@ndpharmabiotech.com